Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes

Arianne Aslamy, Eunjin Oh, Miwon Ahn, Abu Saleh Md Moin, Mariann Chang, Molly Duncan, Jeannette Hacker-Stratton, Mohamed El-Shahawy, Fouad Kandeel, Linda DiMeglio, Debbie C. Thurmond

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Context: Efforts to preserve β-cell mass in the preclinical stages of type 1 diabetes (T1D) are limited by few blood-derived biomarkers of β-cell destruction. Objective: Platelets are proposed sources of blood-derived biomarkers for a variety of diseases, and they show distinct proteomic changes in T1D. Thus, we investigated changes in the exocytosis protein, double C2 domain protein-β (DOC2B) in platelets and islets from T1D humans, and prediabetic nonobese diabetic (NOD) mice. Design, Patients, and Main Outcome Measure: Protein levels of DOC2B were assessed in platelets and islets from prediabeticNODmice and humans, with and without T1D. Seventeen new-onset T1D human subjects (10.3 ± 3.8 years) were recruited immediately following diagnosis, and platelet DOC2B levels were compared with 14 matched nondiabetic subjects (11.4 ± 2.9 years). Furthermore, DOC2B levels were assessed in T1D human pancreatic tissue samples, cytokine-stimulated human islets ex vivo, and platelets from T1D subjects before and after islet transplantation. Results: DOC2B protein abundancewas substantially reduced in prediabeticNODmouse platelets, and these changes were mirrored in the pancreatic islets from the same mice. Likewise, human DOC2B levels were reduced over twofold in platelets fromnew-onset T1D human subjects, and this reduction wasmirrored in T1D human islets. Cytokine stimulation of normal islets reduced DOC2B expression ex vivo. Remarkably, platelet DOC2B levels increased after islet transplantation in patients with T1D. Conclusions: Reduction of DOC2B is an early feature of T1D, and DOC2B abundance may serve as a valuable in vivo indicator of β-cell mass and an early biomarker of T1D.

Original languageEnglish (US)
Pages (from-to)1966-1976
Number of pages11
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Exocytosis
Biomarkers
Medical problems
Type 1 Diabetes Mellitus
Platelets
Blood Platelets
Proteins
Islets of Langerhans Transplantation
Blood
Cytokines
Inbred NOD Mouse
Islets of Langerhans
Proteomics
Outcome Assessment (Health Care)
Tissue

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Aslamy, A., Oh, E., Ahn, M., Moin, A. S. M., Chang, M., Duncan, M., ... Thurmond, D. C. (2018). Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 103(5), 1966-1976. https://doi.org/10.1210/jc.2017-02492

Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. / Aslamy, Arianne; Oh, Eunjin; Ahn, Miwon; Moin, Abu Saleh Md; Chang, Mariann; Duncan, Molly; Hacker-Stratton, Jeannette; El-Shahawy, Mohamed; Kandeel, Fouad; DiMeglio, Linda; Thurmond, Debbie C.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 5, 01.05.2018, p. 1966-1976.

Research output: Contribution to journalArticle

Aslamy, A, Oh, E, Ahn, M, Moin, ASM, Chang, M, Duncan, M, Hacker-Stratton, J, El-Shahawy, M, Kandeel, F, DiMeglio, L & Thurmond, DC 2018, 'Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 5, pp. 1966-1976. https://doi.org/10.1210/jc.2017-02492
Aslamy, Arianne ; Oh, Eunjin ; Ahn, Miwon ; Moin, Abu Saleh Md ; Chang, Mariann ; Duncan, Molly ; Hacker-Stratton, Jeannette ; El-Shahawy, Mohamed ; Kandeel, Fouad ; DiMeglio, Linda ; Thurmond, Debbie C. / Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. In: Journal of Clinical Endocrinology and Metabolism. 2018 ; Vol. 103, No. 5. pp. 1966-1976.
@article{622b0653404f489a96fb703d3575db6b,
title = "Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes",
abstract = "Context: Efforts to preserve β-cell mass in the preclinical stages of type 1 diabetes (T1D) are limited by few blood-derived biomarkers of β-cell destruction. Objective: Platelets are proposed sources of blood-derived biomarkers for a variety of diseases, and they show distinct proteomic changes in T1D. Thus, we investigated changes in the exocytosis protein, double C2 domain protein-β (DOC2B) in platelets and islets from T1D humans, and prediabetic nonobese diabetic (NOD) mice. Design, Patients, and Main Outcome Measure: Protein levels of DOC2B were assessed in platelets and islets from prediabeticNODmice and humans, with and without T1D. Seventeen new-onset T1D human subjects (10.3 ± 3.8 years) were recruited immediately following diagnosis, and platelet DOC2B levels were compared with 14 matched nondiabetic subjects (11.4 ± 2.9 years). Furthermore, DOC2B levels were assessed in T1D human pancreatic tissue samples, cytokine-stimulated human islets ex vivo, and platelets from T1D subjects before and after islet transplantation. Results: DOC2B protein abundancewas substantially reduced in prediabeticNODmouse platelets, and these changes were mirrored in the pancreatic islets from the same mice. Likewise, human DOC2B levels were reduced over twofold in platelets fromnew-onset T1D human subjects, and this reduction wasmirrored in T1D human islets. Cytokine stimulation of normal islets reduced DOC2B expression ex vivo. Remarkably, platelet DOC2B levels increased after islet transplantation in patients with T1D. Conclusions: Reduction of DOC2B is an early feature of T1D, and DOC2B abundance may serve as a valuable in vivo indicator of β-cell mass and an early biomarker of T1D.",
author = "Arianne Aslamy and Eunjin Oh and Miwon Ahn and Moin, {Abu Saleh Md} and Mariann Chang and Molly Duncan and Jeannette Hacker-Stratton and Mohamed El-Shahawy and Fouad Kandeel and Linda DiMeglio and Thurmond, {Debbie C.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1210/jc.2017-02492",
language = "English (US)",
volume = "103",
pages = "1966--1976",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes

AU - Aslamy, Arianne

AU - Oh, Eunjin

AU - Ahn, Miwon

AU - Moin, Abu Saleh Md

AU - Chang, Mariann

AU - Duncan, Molly

AU - Hacker-Stratton, Jeannette

AU - El-Shahawy, Mohamed

AU - Kandeel, Fouad

AU - DiMeglio, Linda

AU - Thurmond, Debbie C.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Context: Efforts to preserve β-cell mass in the preclinical stages of type 1 diabetes (T1D) are limited by few blood-derived biomarkers of β-cell destruction. Objective: Platelets are proposed sources of blood-derived biomarkers for a variety of diseases, and they show distinct proteomic changes in T1D. Thus, we investigated changes in the exocytosis protein, double C2 domain protein-β (DOC2B) in platelets and islets from T1D humans, and prediabetic nonobese diabetic (NOD) mice. Design, Patients, and Main Outcome Measure: Protein levels of DOC2B were assessed in platelets and islets from prediabeticNODmice and humans, with and without T1D. Seventeen new-onset T1D human subjects (10.3 ± 3.8 years) were recruited immediately following diagnosis, and platelet DOC2B levels were compared with 14 matched nondiabetic subjects (11.4 ± 2.9 years). Furthermore, DOC2B levels were assessed in T1D human pancreatic tissue samples, cytokine-stimulated human islets ex vivo, and platelets from T1D subjects before and after islet transplantation. Results: DOC2B protein abundancewas substantially reduced in prediabeticNODmouse platelets, and these changes were mirrored in the pancreatic islets from the same mice. Likewise, human DOC2B levels were reduced over twofold in platelets fromnew-onset T1D human subjects, and this reduction wasmirrored in T1D human islets. Cytokine stimulation of normal islets reduced DOC2B expression ex vivo. Remarkably, platelet DOC2B levels increased after islet transplantation in patients with T1D. Conclusions: Reduction of DOC2B is an early feature of T1D, and DOC2B abundance may serve as a valuable in vivo indicator of β-cell mass and an early biomarker of T1D.

AB - Context: Efforts to preserve β-cell mass in the preclinical stages of type 1 diabetes (T1D) are limited by few blood-derived biomarkers of β-cell destruction. Objective: Platelets are proposed sources of blood-derived biomarkers for a variety of diseases, and they show distinct proteomic changes in T1D. Thus, we investigated changes in the exocytosis protein, double C2 domain protein-β (DOC2B) in platelets and islets from T1D humans, and prediabetic nonobese diabetic (NOD) mice. Design, Patients, and Main Outcome Measure: Protein levels of DOC2B were assessed in platelets and islets from prediabeticNODmice and humans, with and without T1D. Seventeen new-onset T1D human subjects (10.3 ± 3.8 years) were recruited immediately following diagnosis, and platelet DOC2B levels were compared with 14 matched nondiabetic subjects (11.4 ± 2.9 years). Furthermore, DOC2B levels were assessed in T1D human pancreatic tissue samples, cytokine-stimulated human islets ex vivo, and platelets from T1D subjects before and after islet transplantation. Results: DOC2B protein abundancewas substantially reduced in prediabeticNODmouse platelets, and these changes were mirrored in the pancreatic islets from the same mice. Likewise, human DOC2B levels were reduced over twofold in platelets fromnew-onset T1D human subjects, and this reduction wasmirrored in T1D human islets. Cytokine stimulation of normal islets reduced DOC2B expression ex vivo. Remarkably, platelet DOC2B levels increased after islet transplantation in patients with T1D. Conclusions: Reduction of DOC2B is an early feature of T1D, and DOC2B abundance may serve as a valuable in vivo indicator of β-cell mass and an early biomarker of T1D.

UR - http://www.scopus.com/inward/record.url?scp=85047199623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047199623&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-02492

DO - 10.1210/jc.2017-02492

M3 - Article

C2 - 29506054

AN - SCOPUS:85047199623

VL - 103

SP - 1966

EP - 1976

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -